Methylprednisoloneacetate + Lidocaine
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Knee Joint Osteoarthrosis
Conditions
Knee Joint Osteoarthrosis, Hyperalgesia, Severe Movement Related Pain
Trial Timeline
Oct 1, 2014 → Mar 1, 2016
NCT ID
NCT02253966About Methylprednisoloneacetate + Lidocaine
Methylprednisoloneacetate + Lidocaine is a phase 2 stage product being developed by Lundbeck for Knee Joint Osteoarthrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02253966. Target conditions include Knee Joint Osteoarthrosis, Hyperalgesia, Severe Movement Related Pain.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02253966 | Phase 2 | Completed |
Competing Products
20 competing products in Knee Joint Osteoarthrosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2828360 + Placebo | Eli Lilly | Phase 2 | 52 |
| UBX0101 or placebo | Unity Biotechnology | Pre-clinical | 15 |
| UBX0101 | Unity Biotechnology | Phase 1 | 25 |
| UBX0101 | Unity Biotechnology | Phase 2 | 44 |
| UBX0101 | Unity Biotechnology | Phase 1 | 25 |
| YH23537 + Celecoxib + YH23537 placebo | Yuhan | Phase 2 | 52 |
| YM150 + Warfarin | Astellas Pharma | Phase 2 | 52 |
| ASP7962 + Naproxen + Placebo | Astellas Pharma | Phase 2 | 52 |
| Capsaicin Topical Solution | Astellas Pharma | Approved | 85 |
| CGS-200-1 + CGS-200-5 + CGS-200 Vehicle | Astellas Pharma | Phase 2 | 52 |
| MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Duloxetine + Placebo | Shionogi | Phase 3 | 77 |
| Duloxetine | Shionogi | Phase 3 | 77 |
| V120083 + Naproxen + Placebo | Shionogi | Phase 2 | 52 |
| ONO-4474 + Placebo matching ONO-4474 | Ono Pharmaceutical | Phase 2 | 52 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine (DLX) + Placebo (PLA) | Eli Lilly | Phase 3 | 77 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + LY545694 49 mg + LY545694 105 mg | Eli Lilly | Phase 2 | 52 |
| LY517717 + enoxaparin | Eli Lilly | Phase 2 | 52 |